التفاصيل البيبلوغرافية
| العنوان: |
Troponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA -Related Dilated Cardiomyopathy. |
| المؤلفون: |
Chmielewski, Przemysław, Kowalik, Ilona, Truszkowska, Grażyna, Michalak, Ewa, Ponińska, Joanna, Sadowska, Agnieszka, Kalin, Katarzyna, Jaworski, Krzysztof, Minota, Ilona, Krzysztoń-Russjan, Jolanta, Zieliński, Tomasz, Płoski, Rafał, Bilińska, Zofia Teresa |
| المصدر: |
Journal of Clinical Medicine; Jun2024, Vol. 13 Issue 11, p3164, 8p |
| مصطلحات موضوعية: |
VENTRICULAR arrhythmia, BRAIN natriuretic factor, HEART failure, DILATED cardiomyopathy, TROPONIN, GENETIC testing, RECEIVER operating characteristic curves |
| مستخلص: |
Background: LMNA-related dilated cardiomyopathy (LMNA-DCM) caused by mutations in the lamin A/C gene (LMNA) is one of the most common forms of hereditary DCM. Due to the high risk of mutation transmission to offspring and the high incidence of ventricular arrhythmia and sudden death even before the onset of heart failure symptoms, it is very important to identify LMNA-mutation carriers. However, many relatives of LMNA-DCM patients do not report to specialized centers for clinical or genetic screening. Therefore, an easily available tool to identify at-risk subjects is needed. Methods: We compared two cohorts of young, asymptomatic relatives of DCM patients who reported for screening: 29 LMNA mutation carriers and 43 individuals from the control group. Receiver operating characteristic (ROC) curves for potential indicators of mutation carriership status were analyzed. Results: PR interval, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity cardiac troponin T (hscTnT) serum levels were higher in the LMNA mutation carrier cohort. Neither group differed significantly with regard to creatinine concentration or left ventricular ejection fraction. The best mutation carriership discriminator was hscTnT level with an optimal cut-off value at 5.5 ng/L, for which sensitivity and specificity were 86% and 93%, respectively. The median hscTnT level was 11.0 ng/L in LMNA mutation carriers vs. <3.0 ng/L in the control group, p < 0.001. Conclusions: Wherever access to genetic testing is limited, LMNA mutation carriership status can be assessed reliably using the hscTnT assay. Among young symptomless relatives of LMNA-DCM patients, a hscTnT level >5.5 ng/L strongly suggests mutation carriers. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Medicine is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder